期刊
VIROLOGY JOURNAL
卷 19, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12985-021-01737-3
关键词
SARS-CoV-2 variant; Inactivated vaccine; Mutant RBD vaccine; Sequential immunization; Broadly neutralizing antibody
类别
资金
- National Science Fund for Distinguished Young Scholars [82025022]
- National Natural Science Foundation of China [82002140, 82171752, 82101861]
- Guangdong Basic and Applied Basic Research Foundation [2021B1515020034, 2019A1515011197, 2021A1515011009, 2020A1515110656]
- Shenzhen Science and Technology Program [RCYX20200714114700046, JSGG20200207155251653, JSGG20200807171401008, KQTD20200909113758004, JCYJ20190809115617365]
This study suggests that a third booster dose of a heterologous RBD vaccine after two doses of inactivated vaccines can significantly enhance neutralizing antibody responses against various SARS-CoV-2 variants. The findings highlight the potential of heterologous vaccines in the development of next-generation COVID-19 vaccines.
The current COVID-19 pandemic caused by constantly emerging SARS-CoV-2 variants still poses a threat to public health worldwide. Effective next-generation vaccines and optimized booster vaccination strategies are urgently needed. Here, we sequentially immunized mice with a SARS-CoV-2 wild-type inactivated vaccine and a heterologous mutant RBD vaccine, and then evaluated their neutralizing antibody responses against variants including Beta, Delta, Alpha, Iota, Kappa, and A.23.1. These data showed that a third booster dose of heterologous RBD vaccine especially after two doses of inactivated vaccines significantly enhanced the GMTs of nAbs against all SARS-CoV-2 variants we tested. In addition, the WT and variants all displayed good cross-immunogenicity and might be applied in the design of booster vaccines to induce broadly neutralizing antibodies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据